SCHEMBL218007

SCHEMBL218007

Clc1ccc(-c2cccnn2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.49
EP300 Q09472 1/20 0.44
HDAC4 P56524 2/20 0.43
DHODH Q02127 1/20 0.43
GRM5 P41594 1/20 0.41
CYP1A2 P05177 1/20 0.41
RAB9A P51151 5/20 0.41
NPC1 O15118 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 1/20 0.40
CYP19A1 P11511 1/20 0.40
FLT3 P36888 1/20 0.40
GSK3B P49841 1/20 0.40
METAP2 P50579 1/20 0.39
NOTUM Q6P988 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MAOB P27338 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30661720 1.00 L3MBTL1 (0.49) L3MBTL1EP300HDAC4DHODHGRM5
SCHEMBL13458062 0.80 GABRA1 (0.52) HDAC4DHODHRAB9ANPC1SMN1; SMN2
SCHEMBL121970 0.79 RAB9A (0.50) HDAC4DHODHRAB9ANPC1SMN1; SMN2
SCHEMBL29959678 0.79 RAB9A (0.50) HDAC4DHODHRAB9ANPC1SMN1; SMN2
SCHEMBL6850684 0.78 SLC6A2 (0.49) L3MBTL1HDAC4DHODHRAB9ANPC1
SCHEMBL8467926 0.78 HDAC4 (0.46) HDAC4DHODHRAB9ANPC1SMN1; SMN2
SCHEMBL16780594 0.78 HDAC4 (0.46) HDAC4DHODHRAB9ANPC1SMN1; SMN2
SCHEMBL3458918 0.78 NPY5R (0.47) L3MBTL1HDAC4DHODHRAB9ANPC1
SCHEMBL8138043 0.78 MAPT (0.56) HDAC4DHODHRAB9ANPC1SMN1; SMN2
SCHEMBL30719418 0.78 HDAC4 (0.46) HDAC4DHODHRAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108250677-B Polymer-based composite material containing filler particle three-dimensional network and preparation method thereof 中国科学院深圳先进技术研究院 2022-10-14 CN claimed
CN-114479734-A Insulating adhesive film, preparation method and application thereof 深圳先进电子材料国际创新研究院 2022-05-13 CN claimed
US-20150168415-A1 COMPOUNDS AND METHODS FOR ANALYSIS AND SYNTHESIS OF SACCHARIDE COMPOUNDS ACADEMIA SINICA (TW) 2015-06-18 US claimed
CN-114530563-B Organic light emitting device, display device, electronic apparatus, in-vehicle display, and vehicle 上海天马微电子有限公司 2026-05-12 CN disclosed
CN-114276304-B A process for preparing 1, 5-benzodiazepine derivatives as pharmaceutical intermediates containing fused rings 南京苏亦欣医药科技有限公司 2024-07-02 CN disclosed
CN-114068834-B Organic light emitting device, display device, electronic apparatus, vehicle-mounted display screen, and vehicle 武汉天马微电子有限公司 2024-04-19 CN disclosed
CN-117050020-A Synthesis method of pyridazine 温州大学新材料与产业技术研究院 2023-11-14 CN disclosed
CN-114890952-B Preparation method of 5-halogeno-2-aminobenzoazacyclic compound 重庆医科大学 2023-06-06 CN disclosed
CN-115135697-A Process for producing polythioether compound 株式会社大赛璐 2022-09-30 CN disclosed
CN-114530563-A Organic light emitting device, display device, electronic apparatus, in-vehicle display, and vehicle 上海天马微电子有限公司 2022-05-24 CN disclosed
CN-114479734-A Insulating adhesive film, preparation method and application thereof 深圳先进电子材料国际创新研究院 2022-05-13 CN disclosed
US-20060073472-A1 Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death UNIVERSITE DE STRASBOURG (FR) 2006-04-06 US disclosed
CN-1628109-A Novel aryl-and heteroaryl-piperazines NOVO NORDISK AS (DK) 2005-06-15 CN disclosed
EP-1430033-A4 ANTI-INFLAMMATORY AND PROTEIN KINASE INHIBITOR COMPOSITION AND METHOD OF USE UNIV NORTHWESTERN (US) 2004-12-15 EP disclosed
EP-1430033-A1 ANTI-INFLAMMATORY AND PROTEIN KINASE INHIBITOR COMPOSITION AND METHOD OF USE NORTHWESTERN UNIVERSITY (US) 2004-06-23 EP disclosed
US-20030176437-A1 Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2003-09-18 US disclosed
WO-2003018563-A1 ANTI-INFLAMMATORY AND PROTEIN KINASE INHIBITOR COMPOSITION AND METHOD OF USE NORTHWESTERN UNIVERSITY (US) 2003-03-06 WO disclosed
EP-0650480-B1 1-ARYLSULPHONYL-3-PHENYL-1,4,5,6-TETRAHYDROPYRIDAZINES ORTHO PHARMA CORP (US) 2001-11-21 EP disclosed
US-5684151-A PROGESTIN AGONISTS ORTHO PHARMACEUTICAL CORPORATION (US) 1997-11-04 US disclosed
WO-1994001412-A1 1-ARYLSULPHONYL, ARYLCARBONYL AND 1-ARYLPHOSPHONYL-3-PHENYL-1,4,5,6-TETRAHYDROPYRIDAZINES ORTHO PHARMACEUTICAL CORPORATION (US) 1994-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060073472-A1 Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death CASP2, CASP1, DAPK2 L3MBTL1 1685/4885EP300 709/4885HDAC4 1068/4885
US-20030176437-A1 Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death CASP2, CASP1, DAPK2 L3MBTL1 1685/4885EP300 709/4885HDAC4 1068/4885
US-20150168415-A1 COMPOUNDS AND METHODS FOR ANALYSIS AND SYNTHESIS OF SACCHARIDE COMPOUNDS MPI, GPI, FUT6 L3MBTL1 3003/4885EP300 4112/4885HDAC4 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.